This prospective observational study aims to evaluate the relationship between hematological inflammatory indices and clinical treatment response in patients with neuropathic pain undergoing sympathetic nerve block procedures as part of routine clinical care. Hematological parameters including neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), monocyte-to-lymphocyte ratio (MLR), systemic immune-inflammation index (SII), systemic inflammation response index (SIRI), aggregate index of systemic inflammation (AISI), and red cell distribution width (RDW) will be evaluated before and after treatment. The association between changes in these indices and pain outcomes will be analyzed.
Eligibility
Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria:
* Age ≥18 years
* Diagnosis of neuropathic pain based on clinical evaluation
* DN4 and/or LANSS scores compatible with neuropathic pain
* Undergoing sympathetic nerve block as part of routine clinical treatment
* Availability of pre-treatment and follow-up hemogram parameters
* Ability to provide written informed consent
Exclusion Criteria:
* Age \<18 years
* Active infection or acute inflammatory disease
* Active malignancy
* History of hematological disease
* Immunosuppressive therapy or systemic corticosteroid use
* Major surgery or severe trauma within the last month
* Pregnancy or breastfeeding
* Autoimmune or rheumatologic inflammatory disease
* Missing follow-up data
Primary outcome measure(s)
Treatment Response at Month 3 — 3 th month Treatment response will be defined as achieving at least 50% reduction in Numeric Rating Scale (NRS) pain score compared with baseline.
NRS 0 means = no pain NRS 10 means= worst pain imaginable
Trial sites (1)
Facility
City
Region
Status
Ankara Bilkent City Hospital
Ankara
Cankaya
Recruiting
More Ankara City Hospital Bilkent trials in Turkey
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.
